Lamsil When Can I Drink Again

What is Lamisil and how is it used?

Lamisil is a prescription medicine used to treat symptoms of fungus (Onychomycosis) of the toenail or fingernail. Lamisil may be used lone or with other medications.

Lamisil belongs to a class of drugs called Antifungals, Systemic.

It is not known if Lamisil is safe and effective in children.

What are the possible side furnishings of Lamisil?

Lamisil may crusade serious side effects including:

• changes in your sense of taste or smell,
• depressed mood,
• sleep problems,
• lack of involvement in daily activity,
• feeling anxious or restless,
• pale peel,
• easy bruising,
• unusual haemorrhage (nose, mouth, vagina or rectum),
• purple or scarlet pinpoint spots nether your skin
• ,
• swelling,
• rapid weight gain,
• little or no urinating,
• blood in your urine or stools,
• weight loss due to taste changes or loss of appetite,
• nausea,
• upper stomach pain,
• vomiting,
• tiredness,
• nighttime urine,
• clay-colored stools,
• yellowing of the skin or optics (jaundice),
• skin sores, and
• butterfly-shaped pare rash on your cheeks or olfactory organ that worsens in sunlight

Get medical help right away, if y'all have whatever of the symptoms listed in a higher place.

The most mutual side effects of Lamisil include:

• diarrhea,
• nausea,
• gas,
• stomach hurting or upset,
• rash,
• headache, and
• abnormal liver role tests

Tell your doctor if y'all have any side effect that bothers you or that does not go abroad.

These are not all the possible side effects of Lamisil. For more information, enquire your doctor or chemist.

Call your physician for medical advice well-nigh side effects. You may report side effects to FDA at 1-800-FDA-1088.

DESCRIPTION

Lamisil Tablets contain the synthetic allylamine antifungal compound terbinafine hydrochloride. Chemically, terbinafine hydrochloride is (E)-N-(6,vi-dimethyl-two-hepten-4-ynyl)-North-methyl-1- naphthalenemethanamine hydrochloride. The empirical formula C₂₁H₂₆CIN with a molecular weight of 327.90, and the following structural formula:

Terbinafine hydrochloride is a white to off-white fine crystalline powder. It is freely soluble in methanol and methylene chloride, soluble in ethanol, and slightly soluble in water.

Each tablet contains:

Active Ingredients: terbinafine hydrochloride (equivalent to 250 mg base)

Inactive Ingredients: colloidal silicon dioxide NF, hydroxypropyl methylcellulose USP, magnesium stearate NF, microcrystalline cellulose NF, and sodium starch glycolate NF.

DOSAGE AND Assistants

Fingernail onychomycosis: One 250 mg tablet once daily for 6 weeks.

Toenail onychomycosis: One 250 mg tablet once daily for 12 weeks.

The optimal clinical effect is seen some months afterward mycological cure and cessation of treatment. Thisis related to the period required for outgrowth of healthy nail.

HOW SUPPLIED

Dosage Forms And Strengths

Tablet, 250 mg white to xanthous-tinged white circular, bi-convex, beveled tablets imprinted with "LAMISIL" in circular form on one side and code "250" on the other side.

Storage And Handling

Lamisil Tablets are supplied as white to xanthous-tinged white circular, bi-convex, askew tablets containing 250 mg of terbinafine imprinted with "LAMISIL" in circular class on 1 side and code "250" on the other.

Bottles of 100 tablets NDC 0078-0179-05
Bottles of 30 tablets NDC 0078-0179-15

Store Lamisil Tablets beneath 25°C (77°F); in a tight container. Protect from lite.

Distributed past: Novartis Pharmaceuticals Corporation, East Hanover, New Bailiwick of jersey 07936. Revised: Feb 2015

SIDE EFFECTS

Clinical Trials Experience

Because clinical trials are conducted nether widely varying conditions, adverse reaction rates in the clinical trials of a drug cannot exist direct compared to rates in the clinical trials of another drug and may non reflect the rates observed in practise.

The almost frequently reported agin events observed in the three The states/Canadian placebo-controlled trials are listed in the table below. The agin events reported encompass gastrointestinal symptoms (including diarrhea, dyspepsia, and abdominal hurting), liver exam abnormalities, rashes, urticaria, pruritus, and gustatory modality disturbances. Changes in the ocular lens and retina have been reported following the apply of Lamisil Tablets in controlled trials. The clinical significance of these changes is unknown. In general, the adverse events were balmy, transient, and did not lead to discontinuation from study participation.

	Adverse Outcome		Discontinuation
	Lamisil Tablets (%) n=465	Placebo (%) n=137	Lamisil Tablets (%) due north=465	Placebo (%) northward=137
Headache	12.9	nine.5	0.ii	0.0
Gastrointestinal Symptoms:
Diarrhea	v.6	2.nine	0.6	0.0
Dyspepsia	4.3	2.9	0.four	0.0
Abdominal Pain	2.four	one.5	0.4	0.0
Nausea	2.half dozen	2.nine	0.ii	0.0
Flatulence	ii.two	2.ii	0.0	0.0
Dermatological Symptoms:
Rash	5.six	ii.2	0.nine	0.seven
Pruritus	ii.8	1.5	0.2	0.0
Urticaria	1.1	0.0	0.0	0.0
Liver Enzyme Abnormalities*	3.3	ane.iv	0.2	0.0
Taste Disturbance	2.eight	0.7	0.ii	0.0
Visual Disturbance	1.1	1.five	0.9	0.0
*Liver enzyme abnormalities ≥ 2x the upper limit of normal range.

Postmarketing Feel

The post-obit adverse events have been identified during postapproval use of Lamisil Tablets. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Blood and lymphatic system disorders: Pancytopenia, agranulocytosis, severe neutropenia, thrombocytopenia, anemia [run into WARNINGS AND PRECAUTIONS]

Allowed arrangement disorders: Serious hypersensitivity reactions e.thou., angioedema and allergic reactions (including anaphylaxis), precipitation and exacerbation of cutaneous and systemic lupus erythematosus [come across WARNINGS AND PRECAUTIONS], serum sickness-like reaction

Psychiatric disorders: Anxiety and depressive symptoms independent of taste disturbance have been reported with use of Lamisil Tablets. In some cases, depressive symptoms have been reported to subside with discontinuance of therapy and to recur with reinstitution of therapy [see WARNINGS AND PRECAUTIONS].

Nervous system disorders: Cases of taste disturbance, including taste loss, have been reported with the use of Lamisil Tablets. It can exist severe enough to event in decreased food intake, weight loss, anxiety, and depressive symptoms. Cases of smell disturbance, including smell loss, have been reported with the utilise of Lamisil Tablets [come across WARNINGS AND PRECAUTIONS]. Cases of paresthesia and hypoesthesia accept been reported with the use of Lamisil Tablets.

Eye disorders: Visual field defects, reduced visual acuity

Ear and labyrinth disorders: Hearing impairment, vertigo, tinnitus

Vascular disorders: Vasculitis

Gastrointestinal disorders: Pancreatitis, airsickness

Hepatobiliary disorders: Cases of liver failure some leading to liver transplant or decease [see WARNINGS AND PRECAUTIONS], idiosyncratic and symptomatic hepatic injury. Cases of hepatitis, cholestasis, and increased hepatic enzymes [see WARNINGS AND PRECAUTIONS] have been seen with the use of Lamisil Tablets.

Skin and subcutaneous tissue disorders: Serious skin reactions [eastward.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, exfoliative dermatitis, bullous dermatitis, and drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome] [see WARNINGS AND PRECAUTIONS], astute generalized exanthematous pustulosis, psoriasiform eruptions or exacerbation of psoriasis, photosensitivity reactions, pilus loss

Musculoskeletal and connective tissue disorders: Rhabdomyolysis, arthralgia, myalgia

General disorders and assistants site weather condition: Malaise, fatigue, influenza-like disease, pyrexia

Investigations: Altered prothrombin time (prolongation and reduction) in patients concomitantly treated with warfarin and increased blood creatine phosphokinase have been reported

DRUG INTERACTIONS

Drug-Drug Interactions

In vivo studies have shown that terbinafine is an inhibitor of the CYP450 2D6 isozyme. Drugs predominantly metabolized by the CYP450 2D6 isozyme include the following drug classes: tricyclic antidepressants, selective serotonin reuptake inhibitors, beta-blockers, antiarrhythmics class 1C (e.1000., flecainide and propafenone) and monoamine oxidase inhibitors Blazon B. Coadministration of Lamisil Tablets should be done with careful monitoring and may require a reduction in dose of the 2D6- metabolized drug. In a study to assess the effects of terbinafine on desipramine in healthy volunteers characterized as normal metabolizers, the administration of terbinafine resulted in a 2-fold increase in Cmax and a 5-fold increase in area under the curve (AUC). In this study, these effects were shown to persist at the last ascertainment at 4 weeks later discontinuation of Lamisil Tablets. In studies in healthy subjects characterized as extensive metabolizers of dextromethorphan (antitussive drug and CYP2D6 probe substrate), terbinafine increases the dextromethorphan/dextrorphan metabolite ratio in urine by xvi- to 97-fold on average. Thus, terbinafine may catechumen extensive CYP2D6 metabolizers to poor metabolizer status.

In vitro studies with man liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, cyclosporine, cisapride and fluvastatin. In vivo drug-drug interaction studies conducted in good for you volunteer subjects showed that terbinafine does non affect the clearance of antipyrine or digoxin. Terbinafine decreases the clearance of caffeine by 19%. Terbinafine increases the clearance of cyclosporine by xv%.

The influence of terbinafine on the pharmacokinetics of fluconazole, cotrimoxazole (trimethoprim and sulfamethoxazole), zidovudine or theophylline was not considered to be clinically significant.

Coadministration of a single dose of fluconazole (100 mg) with a single dose of terbinafine resulted in a 52% and 69% increase in terbinafine Cmax and AUC, respectively. Fluconazole is an inhibitor of CYP2C9 and CYP3A enzymes. Based on this finding, it is probable that other inhibitors of both CYP2C9 and CYP3A4 (due east.1000., ketoconazole, amiodarone) may as well lead to a substantial increase in the systemic exposure (Cmax and AUC) of terbinafine when concomitantly administered.

At that place have been spontaneous reports of increase or subtract in prothrombin times in patients concomitantly taking oral terbinafine and warfarin, even so, a causal human relationship between Lamisil Tablets and these changes has not been established.

Terbinafine clearance is increased 100% by rifampin, a CYP450 enzyme inducer, and decreased 33% by cimetidine, a CYP450 enzyme inhibitor. Terbinafine clearance is unaffected by cyclosporine. There is no information bachelor from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, phenytoins, thiazide diuretics, and calcium channel blockers.

Food Interactions

An evaluation of the outcome of food on Lamisil Tablets was conducted. An increment of less than 20% of the AUC of terbinafine was observed when Lamisil Tablets were administered with nutrient. Lamisil Tablets tin be taken with or without food.

WARNINGS

Included as part of the PRECAUTIONS section.

PRECAUTIONS

Hepatotoxicity

Cases of liver failure, some leading to liver transplant or death, take occurred with the employ of Lamisil Tablets in individuals with and without preexisting liver disease.

In the bulk of liver cases reported in association with use of Lamisil Tablets, the patients had serious underlying systemic conditions. The severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease. Treatment with Lamisil Tablets should be discontinued if biochemical or clinical prove of liver injury develops.

Lamisil Tablets are not recommended for patients with chronic or active liver affliction. Before prescribing Lamisil Tablets, liver part tests should be performed since hepatotoxicity may occur in patients with and without pre-existing liver disease. Periodic monitoring of liver function tests is recommended. Lamisil should be immediately discontinued in case of elevation of liver function tests. Patients prescribed Lamisil Tablets should be warned to report immediately to their doctor any symptoms of persistent nausea, anorexia, fatigue, airsickness, correct upper abdominal hurting or jaundice, dark urine, or pale stools. Patients with these symptoms should discontinue taking oral terbinafine, and the patient’south liver function should exist immediately evaluated.

Taste Disturbance Including Loss of Taste

Taste disturbance, including gustation loss, has been reported with the use of Lamisil Tablets. It can be severe enough to effect in decreased nutrient intake, weight loss, anxiety, and depressive symptoms. Taste disturbance may resolve within several weeks subsequently discontinuation of treatment, simply may exist prolonged (greater than 1 yr), or may be permanent. If symptoms of a taste disturbance occur, Lamisil Tablets should be discontinued.

Odour Disturbance Including Loss Of Olfactory property

Smell disturbance, including loss of smell, has been reported with the use of Lamisil Tablets. Smell disturbance may resolve afterward discontinuation of treatment, only may be prolonged (greater than 1 year), or may exist permanent. If symptoms of a smell disturbance occur, Lamisil Tablets should be discontinued.

Depressive Symptoms

Depressive symptoms have occurred during postmarketing use of Lamisil Tablets. Prescribers should be alarm to the development of depressive symptoms, and patients should be instructed to report depressive symptoms to their dr..

Hematologic Effects

Transient decreases in absolute lymphocyte counts (ALCs) take been observed in controlled clinical trials. In placebo-controlled trials, 8/465 subjects receiving Lamisil Tablets (i.vii%) and 3/137 subjects receiving placebo (2.2%) had decreases in ALC to beneath one thousand/mm³ on ii or more occasions. In patients with known or suspected immunodeficiency, physicians should consider monitoring consummate blood counts if treatment continues for more than than 6 weeks. Cases of severe neutropenia have been reported. These were reversible upon discontinuation of Lamisil Tablets, with or without supportive therapy. If clinical signs and symptoms suggestive of secondary infection occur, a complete blood count should be obtained. If the neutrophil count is ≤ 1000 cells/mm³, Lamisil Tablets should be discontinued and supportive direction started.

Serious Skin/Hypersensitivity Reactions

There accept been postmarketing reports of serious peel/hypersensitivity reactions [east.g., Stevens-Johnson Syndrome, toxic epidermal necrolysis, erythema multiforme, exfoliative dermatitis, bullous dermatitis, and drug reaction with eosinophilia and systemic symptoms (Wearing apparel) syndrome]. Manifestations of Clothes syndrome may include cutaneous reaction (such as rash or exfoliative dermatitis), eosinophilia, and one or more organ complications such every bit hepatitis, pneumonitis, nephritis, myocarditis, and pericarditis. If progressive skin rash or signs/symptoms of the above drug reactions occur, treatment with Lamisil Tablets should exist discontinued.

Lupus Erythematosus

During postmarketing experience, precipitation and exacerbation of cutaneous and systemic lupus erythematosus have been reported in patients taking Lamisil Tablets. Lamisil Tablets should be discontinued in patients with clinical signs and symptoms suggestive of lupus erythematosus.

Laboratory Monitoring

Measurement of serum transaminases (ALT and AST) is advised for all patients before taking Lamisil Tablets.

Patient Counseling Information

See FDA-Approved Patient Labeling (PATIENT INFORMATION)

Patients taking Lamisil Tablets should receive the post-obit information and instructions:

• Advise patients to immediately report to their physician or get emergency assist if they experience whatsoever of the following symptoms: hives, mouth sores, blistering and peeling of peel, swelling of face, lips, tongue, or pharynx, difficulty swallowing or breathing. Lamisil Tablets handling should exist discontinued.
• Advise patients to immediately study to their md any symptoms of persistent nausea, anorexia, fatigue, vomiting, right upper abdominal pain, jaundice, dark urine, or stake stools. Lamisil Tablets treatment should exist discontinued.
• Advise patients to report to their medico whatever signs of gustation disturbance, smell disturbance and/or depressive symptoms, fever, skin eruption, lymph node enlargement, erythema, scaling, loss of pigment, and unusual photosensitivity that tin can result in a rash. Lamisil Tablets treatment should be discontinued.
• Advise patients to minimize exposure to natural and artificial sunlight (tanning beds or UVA/B treatment) while using Lamisil Tablets.
• Suggest patients that if they forget to have Lamisil Tablets, to accept their tablets as soon every bit they remember, unless it is less than 4 hours earlier the adjacent dose is due. Suggest patients to phone call their physician if they take too many Lamisil Tablets.

Nonclinical Toxicology

Carcinogenesis, Mutagenesis, Impairment Of Fertility

In a 28-month oral carcinogenicity study in rats, an increase in the incidence of liver tumors was observed in males at the highest dose tested, 69 mg/kg/day (2x the MRHD based on AUC comparisons of the parent terbinafine); however, even though dose-limiting toxicity was not achieved at the highest tested dose, higher doses were non tested.

The results of a variety of in vitro (mutations in East. coli and S. typhimurium, DNA repair in rat hepatocytes, mutagenicity in Chinese hamster fibroblasts, chromosome aberration, and sister chromatid exchanges in Chinese hamster lung cells), and in vivo (chromosome aberration in Chinese hamsters, micronucleus examination in mice) genotoxicity tests gave no bear witness of a mutagenic or clastogenic potential.

Oral reproduction studies in rats at doses upwards to 300 mg/kg/day (approximately 12x the MRHD based on BSA comparisons) did non reveal any specific effects on fertility or other reproductive parameters. Intravaginal application of terbinafine hydrochloride at 150 mg/24-hour interval in pregnant rabbits did non increase the incidence of abortions or premature deliveries nor bear on fetal parameters.

Use In Specific Populations

Pregnancy

Pregnancy Category B

There are no acceptable and well-controlled studies in pregnant women. Because brute reproduction studies are non e'er predictive of homo response, and because handling of onychomycosis can exist postponed until later pregnancy is completed, information technology is recommended that Lamisil Tablets not be initiated during pregnancy.

Oral reproduction studies accept been performed in rabbits and rats at doses up to 300 mg/kg/day [12x to 23x the maximum recommended human being dose (MRHD), in rabbits and rats, respectively, based on body area (BSA) comparisons] and accept revealed no evidence of impaired fertility or harm to the fetus due to terbinafine.

Nursing Mothers

After oral administration, terbinafine is present in breast milk of nursing mothers. The ratio of terbinafine in milk to plasma is 7:1. Treatment with Lamisil Tablets is not recommended in women who are nursing.

Pediatric Use

The safety and efficacy of Lamisil Tablets have not been established in pediatric patients with onychomycosis.

Geriatric Use

Clinical studies of Lamisil Tablets did non include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from younger subjects. Other reported clinical experience has non identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, commonly starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Renal Impairment

In patients with renal impairment (creatinine clearance less than or equal to 50 mL/min) the use of Lamisil Tablets has not been adequately studied.

Overdosage & Contraindications

OVERDOSE

Clinical feel regarding overdose with oral terbinafine is limited. Doses up to 5 grams (20 times the therapeutic daily dose) have been taken without inducing serious adverse reactions. The symptoms of overdose included nausea, vomiting, intestinal pain, dizziness, rash, frequent urination, and headache.

CONTRAINDICATIONS

Lamisil Tablets are contraindicated in individuals with a history of allergic reaction to oral terbinafine because of the risk of anaphylaxis.

CLINICAL PHARMACOLOGY

Mechanism Of Action

Terbinafine is an allylamine antifungal [run into Microbiology].

Pharmacodynamics

The pharmacodynamics of Lamisil Tablets is unknown.

Pharmacokinetics

Following oral assistants, terbinafine is well captivated ( > 70%) and the bioavailability of Lamisil Tablets every bit a effect of first-pass metabolism is approximately 40%. Peak plasma concentrations of 1 μg/mL appear inside two hours later on a unmarried 250 mg dose; the AUC is approximately four.56 μg&bu;ll;h/mL. An increase in the AUC of terbinafine of less than twenty% is observed when Lamisil Tablets are administered with nutrient.

In plasma, terbinafine is > 99% bound to plasma proteins and there are no specific binding sites. At steady-state, in comparison to a single dose, the peak concentration of terbinafine is 25% higher and plasma AUC increases by a cistron of 2.5; the increment in plasma AUC is consistent with an effective half-life of ~36 hours. Terbinafine is distributed to the sebum and skin. A terminal half-life of 200-400 hours may correspond the wearisome elimination of terbinafine from tissues such equally skin and adipose. Prior to excretion, terbinafine is extensively metabolized by at to the lowest degree 7 CYP isoenzymes with major contributions from CYP2C9, CYP1A2, CYP3A4, CYP2C8, and CYP2C19. No metabolites have been identified that have antifungal activity similar to terbinafine. Approximately 70% of the administered dose is eliminated in the urine.

In patients with renal impairment (creatinine clearance ≤ 50 mL/min) or hepatic cirrhosis, the clearance of terbinafine is decreased past approximately 50% compared to normal volunteers. No outcome of gender on the blood levels of terbinafine was detected in clinical trials. No clinically relevant age-dependent changes in steady-state plasma concentrations of terbinafine accept been reported.

Microbiology

Terbinafine, an allylamine antifungal, inhibits biosynthesis of ergosterol, an essential component of fungal cell membrane, via inhibition of squalene epoxidase enzyme. This results in fungal prison cell death primarily due to the increased membrane permeability mediated by the accumulation of high concentrations of squalene only not due to ergosterol deficiency. Depending on the concentration of the drug and the fungal species test in vitro, terbinafine hydrochloride may be fungicidal. However, the clinical significance of in vitro data is unknown.

Terbinafine has been shown to be active against most strains of the following microorganisms both in vitro and in clinical infections:

Trichophyton mentagrophytes
Trichophyton rubrum

The following in vitro data are bachelor, but their clinical significance is unknown. In vitro, terbinafine exhibits satisfactory MIC'southward against most strains of the following microorganisms; however, the safety and efficacy of terbinafine in treating clinical infections due to these microorganisms have not been established in adequate and well-controlled clinical trials:

Candida albicans
Epidermophyton floccosum
Scopulariopsis brevicaulis

Animal Toxicology And/Or Pharmacology

A wide range of in vivo studies in mice, rats, dogs, and monkeys, and in vitro studies using rat, monkey, and man hepatocytes suggest that peroxisome proliferation in the liver is a rat-specific finding. However, other effects, including increased liver weights and APTT, occurred in dogs and monkeys at doses giving Css trough levels of the parent terbinafine 2-3x those seen in humans at the MRHD. College doses were not tested.

Clinical Studies

The efficacy of Lamisil Tablets in the treatment of onychomycosis is illustrated past the response of subjects with toenail and/or fingernail infections who participated in 3 United states of america/Canadian placebo-controlled clinical trials.

Results of the showtime toenail trial, equally assessed at week 48 (12 weeks of handling with 36 weeks follow-up after completion of therapy), demonstrated mycological cure, defined as simultaneous occurrence of negative KOH plus negative culture, in 70% of subjects. Fifty-nine percent (59%) of subjects experienced effective treatment (mycological cure plus 0% blast involvement or > 5mm of new unaffected nail growth); 38% of subjects demonstrated mycological cure plus clinical cure (0% nail involvement).

In a second toenail trial of dermatophytic onychomycosis, in which nondermatophytes were likewise cultured, similar efficacy against the dermatophytes was demonstrated. The pathogenic part of the nondermatophytes cultured in the presence of dermatophytic onychomycosis has not been established. The clinical significance of this association is unknown.

Results of the fingernail trial, as assessed at week 24 (6 weeks of treatment with xviii weeks follow-up afterwards completion of therapy), demonstrated mycological cure in 79% of subjects, effective treatment in 75% of the subjects, and mycological cure plus clinical cure in 59% of the subjects.

The mean fourth dimension to overall success was approximately 10 months for the starting time toenail trial and iv months for the fingernail trial. In the kickoff toenail trial, for subjects evaluated at least half dozen months after achieving clinical cure and at least one yr after completing therapy with Lamisil Tablets, the clinical relapse charge per unit was approximately 15%.

PATIENT Information

Lamisil
(Lam-i-sil)
(terbinafine hydrochloride) Tablets

What are Lamisil Tablets ?

Lamisil Tablets is a prescription antifungal medicine used to treat fungal infections of the fingernails and toenails (onychomycosis).

Your doctor should practice tests to cheque you for fungal infection of your nails before y'all start Lamisil Tablets.

Information technology is not known if Lamisil Tablets are condom and effective in children for the treatment of onychomycosis.

Who should not accept Lamisil Tablets ?

Practice not take Lamisil Tablets if you are allergic to terbinafine hydrochloride when taken by mouth.

What should I tell my doctor before taking Lamisil Tablets ?

Before you accept Lamisil Tablets , tell your doctor if y'all:

• take or had liver problems
• have a weakened immune arrangement (immunocompromised)
• have lupus (an autoimmune affliction)
• have any other medical weather condition
• are pregnant or plan to become pregnant. It is not known if Lamisil Tablets will impairment your unborn baby. You should not start taking Lamisil Tablets during pregnancy without talking with your doc.
• are breastfeeding or plan to breastfeed. Lamisil can pass into your breast milk and may harm your infant. Talk to your doctor almost the best mode to feed your baby if y'all take Lamisil Tablets.

Tell your md nearly all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Lamisil Tablets may affect the manner other medicines piece of work and other medicines may affect how Lamisil Tablets work. Especially tell your doctor if you accept:

• a medicine for low
• a medicine for high blood pressure
• a medicine for heart problems
• desipramine (Norpramin)
• caffeine
• cyclosporine (Gengraf, Neoral, Sandimmune)
• fluconazole (Diflucan)
• rifampin (Rifater, Rifamate, Rimactane, Rifadine)
• cimetidine (Tagamet)

If you are not sure if your medicine is one listed above, enquire your doctor or pharmacist.

Know the medicines yous have. Go on a list of them to show your doctor and chemist when you go a new medicine.

How should I take Lamisil Tablets ?

• Take Lamisil Tablets exactly as your medico tells you to take information technology.
• Lamisil comes as a tablet that you lot have by mouth.
• Lamisil Tablets are usually taken:
  • i time each day for 6 weeks to treat fungal infections of your fingernail, or
  • 1 time each twenty-four hours for 12 weeks to treat fungal infections of your toenail
• Lamisil Tablets tin can exist taken with or without food.
• If y'all miss a dose of Lamisil Tablets, take it as soon as you lot remember. If information technology is less than 4 hours before your next dose, skip the missed dose. Only take the side by side dose at your regular time.

If yous have also many Lamisil Tablets telephone call your dr.. You lot may have the following symptoms:

• nausea
• vomiting
• stomach (abdomen) pain
• dizziness
• rash
• frequent urination
• headache

What should I avoid while taking Lamisil Tablets ?

• Avoid sunlight. Lamisil Tablets can make your skin sensitive to the sun and the light from sunlamps and tanning beds. You can go a severe sunburn. Use sunscreen and wear a lid and clothes that cover your skin if you have to be in sunlight. Talk to your doctor if y'all become sunburn.

What are the possible side effects of Lamisil Tablets ?

Lamisil Tablets may cause serious side effects, including:

• liver problems that can lead to the need for liver trans institute, or death. Tell your doctor right away if you become any of these symptoms of a liver problem:
  • nausea
  • upper right tummy-area (belly) pain
  • poor appetite
  • yellowing of your peel or optics (jaundice)
  • tiredness
  • dark (tea-colored) urine
  • vomiting
  • stake or low-cal colored stools

Your doctor should practice a blood test to bank check you for liver problems before you take Lamisil Tablets.

• change in taste or los s of sense of taste may happen with Lamisil Tablets and tin be severe. This may meliorate within several weeks afterwards you end taking Lamisil Tablets, but may terminal for a long time or may become permanent. Tell your doctor if yous take:
  • change in taste or loss of taste
  • poor ambition
  • unwanted weight loss
  • anxiousness
  • change in mood or depressive symptoms
• change in smell or loss of smell may happen with Lamisil Tablets. This may amend afterward you end taking Lamisil Tablets, simply may last for a long time or may get permanent.
• depressive symptoms. Tell your physician right away if you have any of these signs or symptoms:
  • feel sad or worthless
  • change in slumber pattern
  • loss of energy or interest in daily activities
  • restlessness
  • mood changes
• low white claret cell count. People taking Lamisil Tablets may have a decrease in white blood cells, especially neutrophils. Y'all may take a higher risk of getting an infection when your white blood jail cell count is depression.
• serious skin or allergic reactions. Tell your doctor right away or go emergency help if you get whatsoever of these symptoms:
  • skin rash, hives, sores in your mouth, or your skin blisters and peels
  • swelling of your confront, eyes, lips, tongue or throat, problem swallowing or breathing
  • drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome – peel rash, fever, bloated lymph glands, involvement of internal organs
• new or worsening lupus (an autoimmune disease). Stop taking Lamisil Tablets and tell your doctor if you get whatsoever of the following:
  • progressive skin rash that is scaly, ruby, shows scarring, or loss of paint
  • unusual sensitivity to the sun that tin can lead to a rash

The most common side effects of Lamisil Tablets include:

• headache
• diarrhea
• rash
• upset stomach
• abnormal liver office tests
• itching
• change in gustation
• nausea
• breadbasket-area (abdomen) pain
• gas

Tell your doctor if you take any side effect that bothers you or that does not get away.

These are not all of the possible side effects of Lamisil Tablets. For information, ask your doctor or pharmacist.

Telephone call your doctor for medical communication about side effects. Yous may report side effects to FDA at one-800-FDA-1088.

How should I store Lamisil Tablets ?

• Store Lamisil Tablets beneath 77°F (25°C)
• Continue Lamisil Tablets in a tightly airtight container and proceed out of the light.

Keep Lamisil Tablets and all medicines out of the reach of children.

General information virtually the safe and effective use of Lamisil Tablets .

Medicines are sometimes prescribed for purposes other than those listed in Patient Information. Do non use Lamisil Tablets for a condition for which it was not prescribed. Do not give Lamisil Tablets to other people, even if they take the same symptoms that you have. Information technology may harm them.

Y'all can ask your chemist or doctor for information virtually Lamisil Tablets that is written for wellness professionals.

What are the ingredients in Lamisil Tablets ?

Active ingredient: terbinafine hydrochloride

Inactive ingredients: colloidal silicon dioxide, hydroxypropyl methylcellulose, magnesium stearate, microcrystalline cellulose, sodium starch glycolate

This Patient Information has been approved past the U.S. Food and Drug Administration.

From

Report Problems to the Food and Drug Assistants

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

wallargoor.blogspot.com

Source: https://www.rxlist.com/lamisil-drug.htm